Document is current
Any future updates will be listed below
-
Authors
Mitchell, James L https://orcid.org/0000-0001-6785-9352
Buckham, Rebecca https://orcid.org/0000-0002-1847-6117
Lyons, Hannah https://orcid.org/0000-0003-0105-1064
Walker, Jessica K https://orcid.org/0000-0003-2586-7172
Yiangou, Andreas https://orcid.org/0000-0001-8905-5734
Sassani, Matilde https://orcid.org/0000-0002-0384-7296
Thaller, Mark https://orcid.org/0000-0001-7772-2157
Grech, Olivia https://orcid.org/0000-0001-5560-802X
Alimajstorovic, Zerin https://orcid.org/0000-0001-5622-8301
Julher, Marianne
Tsermoulas, Georgios
Brock, Kristian https://orcid.org/0000-0002-3921-0166
Mollan, Susan P https://orcid.org/0000-0002-6314-4437
Sinclair, Alexandra J https://orcid.org/0000-0003-2777-5132
-
Funding
Funding for this research was provided by:
Ministry of Defence
Association of British Neurologists and Guarantors of the Brain fellowship
Brain Research UK
National Institute for Health Research (NIHR) clinician scientist fellowship (NIHR-CS-011-028)
Medical Research Council (MR/K015184/1)
Sir Jules Thorn Award for Biomedical Science
- License Information
-
More Information
Article History
Received: 17 May 2022
Accepted: 12 October 2022
First Online: 1 November 2022
Declarations
:
: This study was approved by the West Midlands - Solihull Research Ethics Committee (REF number 17/WM/0179). The trial was registered with ISTCRN (12678718). In accordance with the Declaration of Helsinki, all subjects gave written informed consent to participate in the study.
: JLM was funded by the UK Ministry of Defence for the duration of the study.OG reports scientific consultancy fees from Invex therapeutics (2020).AY reports receiving speaker fees from Teva, UK outside the submitted work.KB works for UCB.Professor Mollan reports other Invex Therapeutics, other Heidelberg engineering during the conduct of the study; other from Chugai-Roche Ltd, other from Janssen, other from Allergan, other from Santen, other from Roche, other from Neurodiem, outside the submitted work.Professor Sinclair reports personal fees from Invex therapeutics in her role as Director with stock holdings, during the conduct of the study; other from Allergan, Novartis, Cheisi and Amgen outside the submitted work.All other authors declare no competing interests.
